Covalon Technologies

Covalon Technologies EBIT per Share

The EBIT per Share of Covalon Technologies (COV.V) as of Oct 15, 2026 is 0.06 CAD. In the previous year, EBIT per Share was 0.09 CAD — a change of -36.12% (lower).

EBIT per Share

0.06CAD

YoY

-36.12%

Last updated:

EBIT per Share of Covalon Technologies is 2025 0.06 CAD. EBIT per Share of Covalon Technologies was 2024 0.09 CAD. It decreases by -36.12% lower compared to the previous year.

The Covalon Technologies EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.18 CAD
Jan 1, 2024
0.09 CAD
Jan 1, 2025
0.06 CAD
Jan 1, 2026 (e)
0.20 CAD
Jan 1, 2027 (e)
0.23 CAD
Jan 1, 2028 (e)
0.28 CAD
Jan 1, 2029 (e)
0.32 CAD
Jan 1, 2030 (e)
0.38 CAD
The Covalon Technologies EBIT per Share history
YEAREBIT per ShareYoY
est0.38CAD+17.80%
est0.32CAD+16.61%
est0.28CAD+19.91%
est0.23CAD+17.56%
est0.20CAD+242.13%
0.06CAD-36.12%
0.09CAD-149.51%
-0.18CAD-49.89%
-0.36CAD-1,220.60%
0.03CAD-113.73%
-0.24CAD-26.14%
-0.32CAD-538.36%
0.07CAD-13.60%
0.08CAD-133.61%
-0.25CAD+208.09%
-0.08CAD-138.31%
0.21CAD-295.79%
-0.11CAD-75.17%
-0.44CAD+0.70%
-0.43CAD+59.17%
-0.27CAD-58.38%
-0.66CAD+28.37%
-0.51CAD+8.98%
-0.47CAD+13.91%
-0.41CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Covalon Technologies Stock analysis

What does Covalon Technologies do? Covalon Technologies Ltd, listed on the TSX Venture Exchange under the ticker COV.V, is a biotechnology company based in Mississauga, Ontario, Canada. Founded in 2004, the company went public on September 3, 2004, with its initial public offering. Covalon specializes in the research, development, manufacturing, and marketing of patent-protected medical products. The company focuses on advanced wound care, infection prevention, and medical device coatings, offering solutions designed to reduce infections, minimize pain, and improve patient outcomes. Its products include specialized medical devices, medical dressings, and advanced technologies for perioperative care, antimicrobial skin protection, and complex wound closure. Covalon operates through two primary business models: developing and selling its own branded products and collaborating with other medical companies through development and licensing agreements. The company emphasizes compassionate care, creating products that are both patient-friendly and tailored for healthcare providers. Headquartered in Mississauga, Covalon leverages its patented technology platforms to address critical needs in medical care, particularly in reducing post-surgical infections and enhancing recovery processes. The company's solutions are intended to support both patients and medical professionals by providing effective, innovative approaches to wound management and infection control. Covalon's portfolio reflects a commitment to advancing medical technology with a focus on practical, patient-centered applications. Covalon Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Covalon Technologies stock

EBIT per Share of Covalon Technologies is 0.06 CAD in 2025.

EBIT per Share of Covalon Technologies changed from 0.09 CAD to 0.06 CAD, representing a -36.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Covalon Technologies since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Covalon Technologies

All Key Metrics — Covalon Technologies